NICE Single Technology Appraisal Guidance No 244 –
Roflumilast for the management of severe chronic obstructive
pulmonary disease
This NICE guidance was published on 25 January 2012. The web
reference for the appraisal and other related documents is:
www.nice.org.uk/TA244
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (635/10) on
this medication for this indication in October 2010. This stated
that:
roflumilast (Daxas®) is not recommended for use
within NHS Scotland for the maintenance treatment of severe chronic
obstructive pulmonary disease (COPD) (forced expiratory volume in 1
second [FEV1] post-bronchodilator <50% predicted) associated
with chronic bronchitis in adult patients with a history of
frequent exacerbations as add on to bronchodilator treatment.
Access the advice of SMC:
3. There is a material difference between the
recommendations of the NICE STA and SMC. Roflumilast was accepted
by NICE for use only in research.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 25 January 2012
